Keros Therapeutics (NASDAQ:KROS) Issues Quarterly Earnings Results

Keros Therapeutics (NASDAQ:KROS) posted its quarterly earnings results on Wednesday. The company reported ($1.14) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.36) by $0.22, Zacks reports. The firm had revenue of $3.04 million for the quarter, compared to analysts’ expectations of $37.32 million. Keros Therapeutics had a negative return on equity of 41.74% and a negative net margin of 27,890.94%.

Keros Therapeutics Price Performance

KROS stock opened at $11.03 on Thursday. The firm has a 50 day simple moving average of $12.76 and a two-hundred day simple moving average of $39.99. The stock has a market cap of $446.83 million, a PE ratio of -2.13 and a beta of 1.39. Keros Therapeutics has a one year low of $9.77 and a one year high of $73.00.

Analysts Set New Price Targets

A number of equities research analysts have commented on KROS shares. Piper Sandler reduced their price target on shares of Keros Therapeutics from $40.00 to $15.00 and set an “overweight” rating for the company in a report on Friday, January 17th. Scotiabank decreased their price objective on Keros Therapeutics from $44.00 to $41.00 and set a “sector outperform” rating for the company in a report on Thursday, January 16th. Truist Financial dropped their target price on shares of Keros Therapeutics from $100.00 to $43.00 and set a “buy” rating on the stock in a research report on Monday, December 23rd. Jefferies Financial Group started coverage on Keros Therapeutics in a report on Tuesday, November 5th. They issued a “buy” rating for the company. Finally, Wedbush lowered Keros Therapeutics from an “outperform” rating to a “neutral” rating and dropped their price target for the stock from $47.00 to $15.00 in a report on Friday, January 17th. Six investment analysts have rated the stock with a hold rating and eight have assigned a buy rating to the stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $51.78.

Keros Therapeutics Company Profile

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.